Dataset opportunity
Bellaseno — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Bellaseno, usable for Diagnostic AI and Computer Vision.
Score
73
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Artificial Intelligence in Diagnostics market was valued at USD 2.0 billion in 2025, with a projected CAGR of 21.7% (2026-2033).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-10
Breast augmentation procedure uses 3D-printed scaffolds
labonline.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Bellaseno holds a significant Medical Imaging Dataset in the Image modality, complemented by associated medical records and industrial data. This rich, multi-faceted collection is specifically suited for developing and training high-precision Diagnostic AI algorithms, particularly for applications in reconstructive medicine, which is Bellaseno's core operational area.
The business value of this data is highlighted by the global AI in Diagnostics market, which was valued at USD 2.0 billion in 2025 and is projected to grow at a CAGR of 21.7%. [1] Despite known access complexities such as strict GDPR compliance, a restrictive licensing agreement with Mentor (Johnson & Johnson) for breast applications, and data being held across German and Australian subsidiaries, the rarity and specificity of this dataset make it a highly valuable asset for AI developers targeting this high-growth market. ⚠ Diligence (valuable data, access to negotiate): Clinical data is subject to strict GDPR and medical privacy regulations.; Exclusive global licensing agreement with Mentor (Johnson & Johnson) may restrict data rights for breast applications.; Data is partially held across German and Australian subsidiaries. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence proves Bellaseno holds a rare, longitudinal medical imaging dataset with up to 6-year follow-up data, directly linking MRI and CT scans to patient outcomes and scaffold manufacturing parameters. This proprietary collection is a critical asset for diagnostic AI companies seeking to train and validate algorithms for predicting post-surgical tissue regeneration and implant performance. In a diagnostic AI market projected to grow at over 21% annually, this dataset offers a significant competitive advantage by enabling the development of next-generation predictive models for personalized medicine.
See dimension details ↓- Dataset Specificity100
dominant 'medical_records', sector healthcare, 4 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity94
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by the rapid **21.7% CAGR** of the **AI in Diagnostics market**, which creates an urgent need for specialized, high-quality training data to build competitive solutions. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — BellaSeno is an ideal target as it is a clinical-stage medtech SME whose core business is developing proprietary resorbable medical scaffolds, generating valuable clinical trial and medical imaging data as a by-product which it does not currently sell. Issues: The company recently signed an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company, which could affect future data right
- Deep Qualification90
⚠ needs review — Bellaseno is a medtech company developing resorbable scaffolds, and the clinical trial data it generates is a byproduct. While this data is highly valuable and coherent with the AI opportunity, an exclusive global licensing agreement with Mentor (Johnson & Johnson) for its main application (breast) severely restricts data access and monetization. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The dataset includes longitudinal clinical records from over 45 patients with up to 6 years of follow-up, providing essential ground-truth data on patient-reported outcomes and tissue retention for training predictive models.
Image collection
This collection contains multi-year post-operative MRI scans that visually document soft tissue retention and vascularization, offering invaluable data for AI models designed to analyze and predict healing trajectories.
Industrial data
The dataset is enriched with proprietary time-series data on the manufacturing parameters and biomechanical properties of the bioresorbable scaffolds, allowing AI to correlate implant design with in-vivo performance.
Geospatial data
The collection includes tabular data derived from the digital segmentation of CT scans, used for the 3D reconstruction of patient-specific scaffolds, which is critical for developing automated 3D modeling AI.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bellaseno Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global Artificial Intelligence in Diagnostics market was valued at USD 2.0 billion in 2025, with a projected CAGR of 21.7% (2026-2033) (source: Grand View Research). [1]. Investment score 73.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Ensoma — Gelegenheid voor medische beeldvormingsdataset
View opportunity →gezondheidszorgSomatechnology — Onderhoudslogboeken Dataset Mogelijkheid
View opportunity →gezondheidszorgPfmmedical — Gelegenheid voor medische beeldvormingsdataset
View opportunity →Data Academy
Learn before you deal
- Zijn uw gegevens geld waard?3 min read
- Hoeveel is een dataset waard?3 min read
- Hoe een datatransactie verloopt3 min read